drugset / Trial / NCT06849492
HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of treatment for recurrent and metastatic advanced first-line triple-negative breast cancer guided by cell surface protein-based subtyping (HIM).
Timeline
- Start
- 2025-04-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Lenvatinib | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | — | — |